A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Onkos Surgical® Launches GenVie ™

A novel Magnesium Bone Scaffolding technology

Today Onkos Surgical® announced the launch of GenVie ™ Magnesium Bone Scaffold, a novel biologic technology that further expands Onkos’ reach in complex limb salvage procedures.  GenVie™ is the first 510(k) cleared magnesium-based bone void filler in the orthopedic marketplace and is available via a private label distribution agreement with Bone Solutions Inc. (OsteoCrete®) announced in late 2019.

GenVie is an injectable and moldable bone void filler with a unique combination of osteoconductive and high compression strength attributes designed to assist with bone repair and regeneration.  The product is intended for surgically created osseous defects or osseous defects created from traumatic injury to the bone and has a reported healing rate of 80% at twenty-six weeks in a preclinical model1.

“We are excited for the launch of GenVie as this product platform provides extraordinary strength, resorption, and handling profile that our customers are looking for.  GenVie provides an elegant solution for use in certain tumor and complex revision cases and compliments our focused and innovative portfolio,” said Patrick Treacy, CEO and Co-Founder of Onkos Surgical.

Onkos continues to bring to market solutions that address the clinical challenges of complex tumor and revision surgery.  The addition of GenVie complements an existing portfolio and pipeline focused on personalized surgical planning, 3D printed limb salvage offerings, and 3D patient-specific joint sparing innovation.  This launch signals the first of numerous product launches planned for Onkos Surgical in 2020.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy